Positive 2-year results for Simponi Aria (Janssen Biotech) in RA
New two-year results of a Phase III study showed that Simponi Aria (golimumab), from Janssen Biotech, for infusion in combination with methotrexate inhibited radiographic progression in patients with moderately to severely active Rheumatoid Arthritis (RA) at week 24, and continued to inhibit radiographic progression through weeks 52 and 100. Analysis of study patients' X-rays showed significant inhibition of the progression of structural damage at week 24 in patients receiving Simponi Aria plus methotrexate compared with patients receiving placebo plus methotrexate.
The continued inhibition of structural damage progression was seen in patients randomized to Simponi Aria through weeks 52 and 100, and inhibition of structural damage progression was observed in patients receiving placebo who crossed over to Simponi Aria at weeks 16 or 24. Data will be presented at the 2013 Annual Meeting of the American College of Rheumatology. The FDA approved Simponia Aria for adults with RA in July 2013.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins